Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT04427930
Active, not recruiting Phase 3

Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial

NCT04427930 · tracked via the Priya Life Science South Korea tracker
Sponsor
R-Bio
Phase
Phase 3
Started
2020-04-13
Last updated
2023-07-10

Condition(s) studied

Knee Osteoarthritis

Investigational drug(s) / intervention(s)

JOINTSTEM →

JOINTSTEM: Autologous Adipose Tissue derived MSCs

Study summary

The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants of Jointstem Phase 3 Clinical Trial * Participates who signed informed consent document of this study Exclusion Criteria: * No applicable

Primary outcome measure(s)

  • Adverse Events — 5 Years
    Incidence of adverse events from baseline to 5 Years

Trial sites (4)

FacilityCityRegionStatus
Keimyung University Dongsan Medical Center Daegu South Korea
KyungHee University Gangdong Hospital Seoul South Korea
Gangnam Severance Hospital Seoul South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital Seoul South Korea

Other trials for the same condition

Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage Active, not recruiting
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial Recruiting
Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis. Enrolling by invitation
MORA Cure for Knee Osteoarthritis With Anterior Knee Pain Active, not recruiting
Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04427930 on ClinicalTrials.gov ↗ ← All trials in South Korea